Progressive degeneration in the central nervous system (CNS) of Huntington’s disease (HD) patients is a relentless debilitating process, resulting from the inheritance of a single gene mutation. With limited knowledge of the underlying pathological molecular mechanisms, pharmaceutical intervention has to-date not provided any effective clinical treatment strategies to attenuate or compensate the neuronal cell death. Attention has therefore turned to biotherapeutic molecules and novel treatment approaches to promote restoration and protection of selectively vulnerable populations of neurons in the HD brain. Rapid advances in vectorology and gene-based medicine over the past decade have opened the way for safe and efficient delivery of biotherapeutics to the CNS. With numerous factors known to regulate the development, plasticity and maintenance of the mammalian nervous system many proteins have emerged as potential therapeutic agents to alleviate HD progression. This investigative study utilised gene delivery vectors derived from the non-pathogenic adeno-associated virus (AAV) to direct high-level expression of brain-derived neurotrophic factor (BDNF), glial cell-line derived neurotrophic factor (GDNF), Bcl-xL or X-linked inhibitor of apoptosis protein (XIAP) within the rodent striatum. Maintenance of the basal ganglia and functional behaviour deficits were assessed following excitotoxic insult of the striatum by quinolinic acid (QA), a neurotoxic model of HD pathology. Enhanced striatal expression of BDNF prior to QA-induced lesioning provided maintenance of the striosome-matrix organisation of the striatum, attenuating impairments of sensorimotor behaviour with a 36-38% increase in the maintenance of DARPP-32 / krox-24 expressing striatal neurons, reduced striatal atrophy and increased maintenance of striatonigral projections. Higher levels of BDNF however induced seizures and weight-loss highlighting the need to provide regulatable control over biotherapeutic protein expression. Continuous high-expression of BDNF or GDNF resulted in a downregulation of intracellular signal mediating proteins including DARPP-32, with AAV-GDNF not found to enhance the overall maintenance of striatal neurons. Neither of the anti-apoptotic factors provided significant protection of transduced striatal neurons but tended towards ameliorating QA-induced behavioural deficits, displaying behaviour – pathology correlations with the survival of parvalbumin-expressing neurons in the globus pallidus. The results of this thesis suggest BDNF as a promising putative biotherapeutic for HD, but emphasises the requirement to control expression following gene delivery, and for further elucidation of the physiological impact that enhanced expression of endogenous factors has on the host cells. Additionally the maintenance of neural networks beyond the caudate-putamen will be vital to ensuring efficient clinical outcomes for HD. / Auckland Medical Research Foundation. Foundation for Research, Science and Technology. The University of Auckland.

The biggest hurdle in success of gene and drug therapy is designing and preparation of suitable bio-nanomaterials to carry the desired nucleic acid and drug to the targeted site. The work described in the present thesis encompasses two different approaches for the delivery of bioactive oligo/polynucleotides and drugs in vitro and in vivo using either cationic lipids or their nanocomposites with different carbon nanomaterials. The idea of using carriers for oligo/polynucleotides and drugs came into existence because of numerous physiological barriers in pathway of delivery of naked oligo/polynucleotides or drugs which reduces the overall activity of these bioactives in biological systems. These barriers trigger scientific research toward the preparation of appropriate biomaterials which can overcome the physiological barriers and improve the activity of bioactive oligo/polynucleotides and drugs in cellular systems. Toward this end, the design and synthesis of different cationic lipids and carbon nanomaterials were undertaken as described in seven chapters of the thesis. A series of novel cationic lipids with structural variability was prepared and used for gene delivery in vitro. They were further tuned chemically to sustain delivery efficiency in high serum percentage during in vitro transfection. These serum compatible lipids were used to perform transfection of reporter gene plasmid and found to be more efficient compared to the some well known commercial products for the same purpose. Another series of novel lipids were synthesized for the targeted gene delivery in vitro. These tryptophan based cholesteryl lipids were used to prepare mixed liposomes. These mixed liposomes were highly efficient in targeting sigma receptor rich HEK293T over sigma receptor negative HeLa cells. Mixed liposomes were also prepared for selective targeting of αvβ3 and αvβ5 integrins in gene transfection protocol using a palmitoyl-RAFT-RGD4 template. A mixed liposomal formulation was developed to carry out anti-sense siRNA mediated knockdown of Smad-2 protein with better efficiency compared to some of the best known commercial products for the same purpose. These mixed liposomes were also highly efficient for regression via induction of p53 mediated apoptosis in xenograft tumors developed in nude mice. Carbon nanomaterials have been extensively explored as nanoscale gene/drug carriers for potential applications. But the challenge is to solubilize these highly hydrophobic materials in aqueous medium for use in biological systems. Although there are reports for covalent modifications of such nanomaterials but it could be done only with the loss of some beneficial features of these materials. Herein a non-covalent technique has been efficiently used to suspend single walled carbon nanotubes in water using biocompatible cationic lipids. These nanosuspensions were used to complex plasmid DNA and transfect them in vitro. They proved to be highly serum compatible DNA carriers which did not drop the efficiency even in very high percentage of serum. Similarly exfoliated graphene was modified with cationic lipid and serum components to improve IC50 of Tamoxifen citrate and Methotrexate to a considerable extent in vitro. The improved Methotrexate formulations were highly efficient for regression in size of xenograft tumors developed in nude mice. Thus, the present thesis entails generation of cationic lipids and carbon nanomaterials based nanocomposites which were not only highly biocompatible themselves but their efficiency was found many fold better compare to some of the best commercial delivery agents. These were useful for the delivery of various bioactive oligo/polynucleotides and drugs in vitro and in vivo.

Gene therapy is a potential strategy for treatment of diseases caused by a gene defect. Recent studies are involved particulary in the cure of diseases caused by single gene defect (cystic fibrosis, haemophilia, muscular dystrophy etc.). Our work is part of a project aiming at developing ex vivo non-viral gene delivery systems that could be used for the treatment of ocular and cardiovascular diseases. The gene vectors are biodegradable polymeric carriers based on poly-α-amino acids. These polyplexes should transfect target cells which are supposed to be seeded on polyimide membranes. The biodegradable polymer membrane will be implanted into the retina or used as a coating for cardiovascular prosthesis. As a cover of the implantable membranes we used polymerized methacrylamide-modified gelatin forming hydrogels and mediating a growth support for transfected cells. We focus on material bio- and immunocompatibility/immunoacceptability. The results indicated a very good bio- and immunocompatibility of the gelatin B hydrogel both in vitro and in vivo. The gelatin B hydrogel did not cause erythrocytes lysis, stimulation of proliferation (spontaneous or mitogen-induced) of mouse or human lymphoid cells, neither production of cytokines or NO in vitro. Histological examination following subcutaneous...

Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumor. The current standard-of-care treatment including surgery, radiation and temozolomide (TMZ) chemotherapy does not prolong the survival satisfactorily. Here we have tested the feasibility, efficacy and safety of a potential gene therapy approach using AAV as gene delivery vehicle for treatment of GBM. Interferon-beta (IFNβ) is a cytokine molecule also having pleiotropic anticancerous properties. Previously it has been shown by our group that AAV mediated local (intracranial) gene delivery of human IFNβ (hIFNβ) could be an effective treatment for non-invasive human glioblastoma (U87) in orthotopic xenograft mouse model.But as one of the major challenges to treat GBM effectively in clinics is its highly invasive property, in the current study we first sought to test the efficacy of our therapeutic model in a highly invasive human GBM (GBM8) xenograft mouse model. One major limitation of using the xenograft mouse model is that these mice are immune-compromised. Moreover, as IFNβ does not interact with cross-species receptors, the influence of immune systems on GBM remains largely untested. Therefore to test the therapeutic approach in an immune-competent mouse model, we next treated a syngeneic mouse GBM model (GL261) in an immune-competent mouse (C57B6) with the gene encoding the species-matched IFNβ (mIFNβ). We also tested if combination of this IFNβ gene therapy with the current standard chemotherapeutic drug (TMZ) is more effective than any one of the therapeutic modes alone. Finally, we tested the long term safety of the AAV-mIFNβ local gene therapy in healthy C57B6 mice. Next, we hypothesized that global genetic engineering of brain cells expressing secretory therapeutic protein like hIFNβ could be more beneficial for treatment of invasive, migratory and distal multifocal GBM. We tested this hypothesis using systemic delivery of AAV9 vectors encoding hIFNβ gene for treatment of GBM8 tumor in nude mice. Using in vivo bioluminescence imaging of tumor associated firefly luciferase activity, long term survival assay and histological analysis of the brains we have shown that local treatment of AAV-hIFNβ for highly invasive human GBM8 is therapeutically beneficial at an early growth phase of tumor. However, systemic delivery route treatment is far superior for treating multifocal distal GBM8 tumors. Nonetheless, for both delivery routes, treatment efficacy is significantly reduced when treated at a later growth phase of the tumor. In syngeneic GL261 tumor model study, we show that local AAV-mIFNβ gene therapy alone or in combination with TMZ treatment can provide significant survival benefit over control or only TMZ treatment, respectively. However, the animals eventually succumb to the tumor. Safety study in the healthy animals shows significant body weight loss in some treatment groups, whereas one group shows long term survival without any weight loss or any noticeable changes in the external appearances. However, histological analysis indicates marked demyelinating neurotoxic effects upon long term exposures to mIFNβ over-expressions in brain. Overall, we conclude from this study that AAV-IFNβ gene therapy has great therapeutic potential for GBM treatment in future, but the therapeutic window is small and long term continuous expression could have severe deleterious effects on health.

Nonviral gene delivery, though limited by inefficiency, has extensive utility in cell therapy, tissue engineering, and diagnostics. Substrate-mediated gene delivery (SMD) increases efficiency and allows transfection at a cell-biomaterial interface, by immobilizing and concentrating nucleic acid complexes on a surface. Efficient SMD generally requires substrates to be coated with serum or other protein coatings to mediate nucleic acid complex immobilization, as well as cell adhesion and growth; however, this strategy limits reproducibility and may be difficult to translate for clinical applications. As an alternative, we screened a chemically defined combinatorial library of 20 different extracellular matrix mimetic substrates containing combinations of (1) different sulfated polysaccharides that are essential extracellular matrix glycosaminoglycans (GAGs), with (2) mimetic peptides derived from adhesion proteins, growth factors, and cell-penetrating domains, for use as SMD coatings. We identified optimal substrates for DNA lipoplex and polyplex SMD transfection of fibroblasts and human mesenchymal stem cells. Optimal extracellular matrix mimetic substrates varied between cell type, donor source, and transfection reagent, but typically contained Heparin GAG and an adhesion peptide. Multiple substrates significantly increased transgene expression (i.e. 2- to 20-fold) over standard protein coatings. Considering previous research of similar ligands, we hypothesize extracellular matrix mimetic substrates modulate cell adhesion, proliferation, and survival, as well as plasmid internalization and trafficking. Our results demonstrate the utility of screening combinatorial extracellular matrix mimetic substrates for optimal SMD transfection towards application- and patient-specific technologies.

No description available.

Trans-2-Aminocyclohexanol (TACH) is a promising model for pH-triggerable molecular switches with a variety of potential applications. In particular, such a switch, when incorporated into cationic liposomes, provides a novel design of the pH-sensitive helper lipids for gene delivery. Protonation of TACH molecules results in a strong intramolecular hydrogen bond between the amino and its neighboring hydroxyl groups, which triggers a conformational flip, and forces changes of the relative position of other substituents on the ring. In this work, a library of TACH-lipids has been designed and built based on structural modifications of both hydrophilic headgroups and hydrophobic tails, and their conformational behavior has been studied by 1 H NMR. NMR-titration has been done to quantitatively monitor the conformational switch for TACH derivatives. It was discovered that conformational behavior of TACH-lipids is independent from the length or shape of their hydrophobic tails. Therefore, a simplified model was suggested based on TACH with diethyl groups instead of hydrocarbon tails. Conformational study of these models has demonstrated that the position of equilibrium shift A [special characters omitted] BH + can be effectively changed by altering structure of NR 2 R 3 group. Furthermore, the pH-induced conformational flip occurs in a certain pH range that mostly depends on the basicity of group NR 2 R 3 , allowing a broad tuning of the pH-sensitivity of TACH-based conformational switches in a wide range of acidity. The hydrophilic OH group was also modified to influence the conformational equilibrium. External stimuli including addition of acid, change of solvent and of the solution ionic strength also showed impact on conformation equilibrium to different extents. To explore the potential to serve as pH-sensitive helper lipids in gene delivery, a variety of TACH-lipids were incorporated into lipoplexes together with the cationic lipid DOTAP to mediate DNA transfection in Bl6F1 and HeLa cancer cell lines. The lipoplex comprising TACH-lipid 3o (R 1 = C 19 H 37 ; R 2 R 3 = CF 3 CH 2 NH) exhibited one to two orders of magnitude better transfection efficiency than the one with the conventional helper lipid DOPE while only inducing slight higher cytotoxicity. Thus, the lipid can be suggested as a novel helper lipid for efficient gene transfection with low cytotoxicity.

Grâce à de récentes percées scientifiques, certains médiateurs clés dans divers états pathologiques ont été identifiés et de nouveaux composés thérapeutiques ont été développés pour les inhiber. Bien que très efficaces, ces composés possèdent souvent des propriétés physico-chimiques incompatibles avec celles du corps humain et deviennent, donc, difficiles à formuler. Au cours des dernières décennies, les systèmes de vectorisation de médicaments ont été étudiés comme une solution potentielle promettant une augmentation de la concentration du médicament au site d'action tout en atténuant les problèmes de stabilité et de solubilité. Plus particulièrement, les polymères ont démontré un succès en tant que matière première dans la conception de ces formulations. Cependant, un obstacle majeur à leur développement clinique est le faible niveau d’encapsulation du principe actif. Afin de remédier à cette limitation, les travaux présentés dans cette thèse se sont concentrés sur l'utilisation de copolymères blocs en forme d'étoile et à base d'acide cholique pour faciliter l'encapsulation. Divers principes actifs aux propriétés physico-chimiques variables ont été encapsulés dans nos systèmes polymères, témoignant ainsi de leur grande efficacité et ceci à travers une large gamme de médicaments. Dans un premier temps, les propriétés physico-chimiques de notre système ont été étudiées. Les copolymères bloc sont composés d'un noyau d'acide cholique (CA) sur lequel le poly (allyl glycidyl éther) (PAGE) et le poly (éthylène glycol) (PEG) sont polymérisées séquentiellement pour donner lieu au CA-(PAGE-b-PEG)4 amphiphiles à quatre branches. De plus, le bloc PAGE a été fonctionnalisé pour porter des groupements amines primaires. Les effets de la longueur du bloc PEG et des groupements amines sur le comportement thermosensible des polymères dans l'eau ont été examinés. Cette thermosensibilité a aussi été étudiée en présence de diverses concentrations de sels. Il a été découvert que l'augmentation de la longueur du PEG augmente la température du point de trouble. De même, la fonctionnalisation des blocs PAGE pour porter des groupements amines a augmenté le point de trouble en l'absence de sel, mais a significativement diminué en présence de sel. Cette observation a été attribuée au « salting-out » des polymères. Dans un second temps, employée comme un médicament hydrophobe modèle, la doxorubicine (Dox) a été encapsulée à l’aide de nos copolymères blocs CA-(PAGE-b-PEG)4. Dans ce cas, les interactions polymère-médicament régissant l’encapsulation de la Dox ont été étudiées. Plus précisément, les interactions hydrophobes et électrostatiques ont été comparées pour leur influence sur la charge de médicament à l'intérieur des copolymères blocs. Une charge élevée de Dox a été obtenue à l’aide des interactions électrostatiques par rapport aux interactions hydrophobes avec ou sans la présence d'acide oléique comme co-tensioactif. De plus, les interactions électrostatiques conféraient au système de relargage une réactivité au pH permettant ainsi un relargage de la Dox en présence d’un pH acide. Les copolymères blocs ont présenté une bonne biocompatibilité lors d’essai in vitro. Les nouveaux copolymères blocs en étoile et à base d'acide cholique ont montré un grand potentiel en tant que vecteurs de relargage de médicaments pour l’encapsulation de la Dox. Pour démontrer l’étendue de l’application de notre système, des petits acides ribonucléiques interférant (pARNi) ont été encapsulés à l’aide des copolymères blocs CA-(PAGE-b-PEG)4 où le PAGE a été fonctionnalisé pour porter des groupements amines. Les pARNi sont des composés thérapeutiques hydrophiles chargés négativement et nécessitant une méthodologie d’encapsulation différente de celle utilisée pour la Dox. Les groupements allyles du bloc PAGE ont été fonctionnalisés pour porter des amines primaires ou tertiaires. Également, l'acide folique a été greffé sur l'extrémité de la chaîne PEG pour augmenter l'absorption cellulaire. Les (CA-PAGE-b-PEG)4 fonctionnalisés avec des amines primaires ou tertiaires ont présenté une forte complexation des pARNi. Des agrégats micellaires uniformes ont ainsi été obtenus. De plus, des lipides ont été ajoutés comme co-tensioactifs pour aider à stabiliser les nanoparticules dans les milieux de culture cellulaire. Ces systèmes micellaires mixtes avaient une charge élevée de pARNi et une absorption cellulaire améliorée avec une augmentation concomitante de la transfection des pARNi dans des cellules modèles de HeLa et HeLa-GFP, respectivement. Les résultats présentés dans cette thèse témoignent du grand potentiel de l'utilisation de copolymères blocs en forme d'étoile et à base d'acide cholique dans la conception de systèmes de vectorisation de médicaments. Ces résultats offrent des conclusions pertinentes sur les différents paramètres clés contrôlant l’efficacité des systèmes de vectorisation des médicaments à base de polymères pouvant être traduits dans d'autres systèmes. Les stratégies développées ici aideront grandement au développement des systèmes de vectorisation de médicaments et accéléreront potentiellement leur évolution vers la clinique. / Recent scientific breakthroughs have fostered the identification of key mediators of various diseased states while permitting the development of novel therapeutic compounds to address them. Although very potent, these compounds often possess physico-chemical properties that are incompatible with those of the human body and are becoming increasingly difficult to formulate. In the recent decades, drug delivery systems have been studied as a potential solution in the formulation of these therapeutic compounds promising improved accumulation at the site of action while mitigating issues of stability and solubility. Most notably, polymers have shown tremendous success as starting material in the design of these drug formulations. However, one major hurdle curtailing their clinical translatability is their low drug loading levels. In an effort to address this limitation, the work presented in this thesis focused on the use of cholic acid-based star-shaped block copolymers for the encapsulation of active pharmaceutical ingredients with varying physico-chemical properties thereby demonstrating their successful application to a broad range of compounds. First, the physico-chemical properties of our proposed system were studied. The block copolymers are composed of a cholic acid (CA) core onto which poly(allyl glycidyl ether) (PAGE) and poly(ethylene glycol) (PEG) are polymerized sequentially to afford an amphiphilic CA-(PAGE-b-PEG)4 with four branches. The PAGE block was further functionalized to bear pendant amine groups. The effects of PEG length and of the amine groups on the thermoresponsive behavior of the polymers in water at various salt concentrations were examined. It was discovered that increasing the length of PEG increases the cloud point temperature. Similarly, functionalizing the PAGE blocks to bear pendant amine groups increased the cloud point in the absence of salt, but significantly decreased the cloud point in the presence of salt. This observation was attributed to the salting-out of the polymers. Acting as a model hydrophobic drug, doxorubicin (Dox) was first encapsulated using our proposed CA-(PAGE-b-PEG)4 block copolymers. In this case, the polymer-drug interactions driving the loading of Dox was studied. Specifically, hydrophobic and electrostatic interactions were compared for their influence on the drug loading inside the block copolymers. A high loading of Dox was achieved vis electrostatic interactions compared to hydrophobic interactions with or without the presence of oleic acid as a cosurfactant. Also, the electrostatic interactions conferred a pH responsiveness to the system where the Dox remained encapsulated at physiological pH but was released in acidic pH. The block copolymers displayed good biocompatibility in vitro. The new functionalized star block copolymers based on cholic acid showed great potential as drug delivery carriers for the loading of Dox. To demonstrate the widespread application of our proposed system, small interfering RNA (siRNA) was loading using the CA-(PAGE-b-PEG)4 block copolymers where PAGE was functionalized with amine. siRNA is a hydrophilic, negatively charged therapeutic compound necessitating a different loading methodology than that used for Dox. The allyl groups of PAGE were functionalized to bear primary or tertiary amines and folic acid was grafted onto the PEG chain end to increase cell uptake. (CA-PAGE-b-PEG)4 functionalized with either primary or tertiary amines show high siRNA complexation. Uniform micellar aggregates were obtained. Lipids were added as co-surfactants to help stabilize the nanoparticles in the cell culture media. The mixed micelles had high siRNA loading and improved cell uptake with a concomitant increase in siRNA transfection in HeLa and HeLa-GFP model cells, respectively. The results presented in this thesis, demonstrate the feasibility of using cholic acid-based star-shaped block copolymers in the design of drug delivery systems and offers insights into key parameters controlling their efficacy which can be translated to other polymer-based systems. The strategies developed herein will greatly aid in the development of drug delivery systems and potentially accelerate their progress into the clinic.

Thèse numérisée par la Division de la gestion de documents et des archives de l'Université de Montréal.

Thèse numérisée par la Division de la gestion de documents et des archives de l'Université de Montréal